SIGLEC1 and glioblastoma: Newly identified CD169+ macrophage subpopulations contribute to antitumor immunity against GBM, facilitating phagocytosis through ligand binding on apoptotic tumor cells and boosting tumor‐specific T‐cell responses through CD169.